← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Bisphosphonates, combinations
ibandronic acid and colecalciferol
M05BB09
Forms & Strengths
- Tablet: ibandronic acid 150 mg / colecalciferol 24,000 IU
Adult Dosing
- Treatment of osteoporosis in postmenopausal women: One tablet once monthly, taken on the same date each month.
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established; use is not recommended.
Indications
- Treatment of osteoporosis in postmenopausal women at risk of vitamin D insufficiency to reduce the risk of fractures.
Mechanism of Action
- Ibandronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption, increasing bone mineral density and reducing bone turnover.
- Colecalciferol (Vitamin D3) is essential for efficient calcium and phosphate absorption in the small intestine and for normal bone mineralization.
Contraindications
- Abnormalities of the esophagus which delay esophageal emptying (e.g., stricture or achalasia)
- Inability to stand or sit upright for at least 60 minutes
- Hypocalcemia
- Hypersensitivity to ibandronate, colecalciferol, or any excipients
Adverse Reactions
- Esophagitis, esophageal ulcers, or erosions
- Musculoskeletal pain
- Hypocalcemia
- Dyspepsia, nausea, abdominal pain
- Osteonecrosis of the jaw (rare)
- Atypical femoral fractures (rare)
Drug Interactions
- Antacids, calcium supplements, and multivalent cation-containing products interfere with the absorption of ibandronate and should be separated by at least 60 minutes.
- Aspirin and NSAIDs may increase gastrointestinal adverse effects.
- Orlistat may impair the absorption of vitamin D (colecalciferol).
Curated Content: Needs Vetting Before Put to Clinical Use